Renaissance of18F-FDG Positron Emission Tomography in the Imaging of Pheochromocytoma/Paraganglioma

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages 2337-2339

  Taïeb, David ^a   Timmers, Henri J L M ^b   Shulkin, Barry L ^c   Pacak, Karel ^d  

^a TIMONE HOSPITAL   (France)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 FLUORODOPAMINE F 18; FLUORODEOXYGLUCOSE F 18; HYDROXYEPHEDRINE C 11; NORADRENALIN TRANSPORTER; RADIOPHARMACEUTICAL AGENT; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE SUBUNIT B; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER;

ANAEROBIC GLYCOLYSIS; CANCER RADIOTHERAPY; CELL RESPIRATION; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; HUMAN; MUTATIONAL ANALYSIS; NORADRENALIN UPTAKE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY; SENSITIVITY ANALYSIS; TUMOR LOCALIZATION;

ADRENAL GLAND NEOPLASMS; DIHYDROXYPHENYLALANINE; FLUORODEOXYGLUCOSE F18; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY;

EID: 84904035079     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1048     Document Type: Note

References (10)

1. Pacák J, Točík Z, Černý M. Synthesis of 2-deoxy-2-fluoro-D-glucose. J Chem Soc D Chem Comm. 1969;77-77.
2. Ido T, Wan CN, Casella V, et al. Labeled 2-deoxy-D-glucose analogs: 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J Labelled Comp Radiopharm. 1978;14:175-183. (Pubitemid 8294308)
3. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-Dglucose PET. Radiology. 1999;212:35-41.
4. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981;305:12-17. (Pubitemid 11071190)
5. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009; 94:4757-4767.
6. Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology. 2002;222:507-512. (Pubitemid 34106126)
7. Gabriel S, Blanchet EM, Sebag F, et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf). 2013;79:170-177.
8. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000;287:848-851. (Pubitemid 30084326)
9. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25: 2262-2269. (Pubitemid 46954653)
10. Timmers HJ, Chen CC, Carrasquillo JA, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104:700-708.